Patents by Inventor Benyamin YAZDAN PANAH

Benyamin YAZDAN PANAH has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12138348
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Grant
    Filed: February 21, 2022
    Date of Patent: November 12, 2024
    Assignee: CureVac SE
    Inventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
  • Publication number: 20240246056
    Abstract: The present invention relates to a manufacturing device for a pharmaceutical product, a manufacturing module for a pharmaceutical product, a manufacturing system for a pharmaceutical product, a method for producing a pharmaceutical product, a method for producing a DNA template, a method for producing an RNA, a method for producing a formulated RNA and uses of the manufacturing device, module or system. The manufacturing device for a pharmaceutical product comprises a housing, a process chamber, a technical chamber, a separation element, and a control unit. The housing is closed relative to the environment outside the housing. The housing encompasses the process chamber and the technical chamber. The process chamber is separated from the technical chamber by the separation element. The control unit is configured to control a gas flow through the process chamber. The control unit is configured to control the gas flow to provide in the process chamber a positive pressure relative to the environment.
    Type: Application
    Filed: September 1, 2021
    Publication date: July 25, 2024
    Applicants: CureVac RNA Printer GmbH, Tesla Automation GmbH
    Inventors: Benyamin YAZDAN PANAH, Tilmann ROOS, Telmo GRACA, Felix BERTSCH, Veronika FONTIUS, Michael RAUEN, Nico SCHOLTES, Philipp HOFFMANN, Martin KUNZE
  • Publication number: 20240100142
    Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.
    Type: Application
    Filed: May 11, 2023
    Publication date: March 28, 2024
    Applicant: CureVac SE
    Inventors: Tilmann ROOS, Martin KUNZE, Benyamin YAZDAN PANAH, Salih YILMAZ, Markus CONZELMANN
  • Publication number: 20230295709
    Abstract: The present invention is concerned with linear double stranded DNA, which is coupled to a single support or a tag at the 3? end of its non-coding strand and methods for producing said linear double stranded DNA. The present invention further relates to the use of said linear double stranded DNA in an RNA in vitro transcription reaction and also to a method for producing RNA in vitro. The present invention also relates to a bioreactor for RNA in vitro transcription.
    Type: Application
    Filed: November 22, 2022
    Publication date: September 21, 2023
    Applicant: CureVac SE
    Inventors: Benyamin YAZDAN PANAH, Tilmann ROOS, Veronika WAGNER, Carola PONGRATZ
  • Publication number: 20230227881
    Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2?-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2?-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5?-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5?-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2?-O-methyltransferase.
    Type: Application
    Filed: January 13, 2023
    Publication date: July 20, 2023
    Applicant: CureVac SE
    Inventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Andreas THESS, Dominik BUOB, Martin KUNZE, Veronika WAGNER
  • Patent number: 11684665
    Abstract: The invention relates to a method for producing a ribonucleic acid (RNA) molecule composition comprising n different RNA molecule species, the method comprising a step of RNA in vitro transcription of a mixture of m different deoxyribonucleic acid (DNA) molecule species in a single reaction vessel in parallel, i.e. simultaneously, and a step of obtaining the RNA molecule composition. Also provided is the RNA composition provided by the inventive method and a pharmaceutical composition comprising the same as well as a pharmaceutical container. Moreover, the invention provides the RNA composition and the pharmaceutical composition for use as medicament.
    Type: Grant
    Filed: December 22, 2016
    Date of Patent: June 27, 2023
    Assignee: CureVac SE
    Inventors: Tilmann Roos, Martin Kunze, Benyamin Yazdan Panah, Salih Yilmaz, Markus Conzelmann
  • Patent number: 11608513
    Abstract: The present invention relates to an immobilized capping enzyme, preferably an immobilized Vaccinia virus capping enzyme. Furthermore, the present invention relates to an immobilized cap-specific nucleoside 2?-O-methyltransferase, preferably an immobilized Vaccinia virus cap-specific nucleoside 2?-O-methyltransferase. Moreover, the present invention relates to a method for immobilizing said enzymes and to a method of using said enzymes for the addition of a 5?-cap structure to RNAs. Moreover, the present invention relates to an enzyme reactor for performing the capping reaction using said immobilized enzymes and the subsequent separation of the 5?-capped RNA product. In addition, the present invention relates to a kit comprising the capping enzyme and/or the cap-specific nucleoside 2?-O-methyltransferase.
    Type: Grant
    Filed: May 30, 2016
    Date of Patent: March 21, 2023
    Assignee: CureVac SE
    Inventors: Tilmann Roos, Benyamin Yazdan Panah, Markus Conzelmann, Andreas Thess, Dominik Buob, Martin Kunze, Veronika Wagner
  • Patent number: 11534405
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: December 27, 2022
    Assignee: CureVac AG
    Inventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
  • Patent number: 11525158
    Abstract: The present invention is concerned with linear double stranded DNA, which is coupled to a single support or a tag at the 3? end of its non-coding strand and methods for producing said linear double stranded DNA. The present invention further relates to the use of said linear double stranded DNA in an RNA in vitro transcription reaction and also to a method for producing RNA in vitro. The present invention also relates to a bioreactor for RNA in vitro transcription.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: December 13, 2022
    Assignee: CureVac SE
    Inventors: Benyamin Yazdan Panah, Tilmann Roos, Veronika Wagner, Carola Pongratz
  • Publication number: 20220387320
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Application
    Filed: July 11, 2022
    Publication date: December 8, 2022
    Applicant: CureVac AG
    Inventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
  • Publication number: 20220389470
    Abstract: The present invention relates to a method for in vitro transcription of a linear template DNA which is produced using an immobilized restriction endonuclease. The invention also relates to mutated restriction enzymes which are suitable for immobilization and a solid support to which these restriction enzymes are immobilized. Further, the present invention relates to an enzyme reactor containing said immobilized restriction endonuclease which enzyme reactor can be used for preparing linearized template DNA. Finally, the present invention relates to the use of said enzyme reactor for preparing a linear template DNA for in vitro transcription. In addition, the present invention relates to a kit comprising the immobilized restriction endonuclease.
    Type: Application
    Filed: August 17, 2022
    Publication date: December 8, 2022
    Applicant: CureVac AG
    Inventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Martin KUNZE
  • Publication number: 20220348976
    Abstract: The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof. Further disclosed is an enzyme reactor and kit comprising the PNP for producing polynucleotidylated ribonucleic acid (poly(N)RNA) molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.
    Type: Application
    Filed: June 13, 2022
    Publication date: November 3, 2022
    Applicant: CureVac AG
    Inventors: Tilmann ROOS, Benyamin YAZDAN PANAH, Markus CONZELMANN, Veronika WAGNER
  • Patent number: 11433027
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Grant
    Filed: August 20, 2020
    Date of Patent: September 6, 2022
    Assignee: CureVac AG
    Inventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
  • Patent number: 11384375
    Abstract: The present invention relates to an immobilized poly(N)polymerase (PNP), methods of producing said PNP and uses thereof. Further disclosed is an enzyme reactor and kit comprising the PNP for producing polynucleotidylated ribonucleic acid poly(N)RNA)molecules which are useful in gene therapy, immunotherapy, protein replacement therapy and/or vaccination.
    Type: Grant
    Filed: May 2, 2016
    Date of Patent: July 12, 2022
    Assignee: CureVac AG
    Inventors: Tilmann Roos, Benyamin Yazdan Panah, Markus Conzelmann, Veronika Wagner
  • Publication number: 20220168225
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-freeze drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Application
    Filed: February 21, 2022
    Publication date: June 2, 2022
    Applicant: CureVac AG
    Inventors: Fabian Johannes EBER, Benyamin YAZDAN PANAH, Stefanie SEWING, Thomas KETTERER, Thorsten MUTZKE, Tilmann ROOS, Michael SONNTAG, Michael WIGGENHORN, Katharina KOLLAND
  • Publication number: 20220119795
    Abstract: The present invention relates to a buffer system comprising a dicarboxylic acid or tricarboxylic acid or a salt thereof for synthesizing RNA molecules as well as a method of RNA in vitro transcription using this buffer system. The present invention also provides the use of this buffer system in RNA in vitro transcription and in the reduction or prevention of precipitates during RNA in vitro transcription.
    Type: Application
    Filed: January 3, 2022
    Publication date: April 21, 2022
    Applicant: CureVac AG
    Inventors: Benyamin YAZDAN PANAH, Aniela WOCHNER, Tilmann ROOS, Andreas FUNKNER, Martin KUNZE
  • Publication number: 20220073962
    Abstract: The present invention is concerned with methods for analyzing RNA molecules. The provided methods involve conjugates for RNA cleavage comprising a chemical moiety with RNA cleaving activity and an oligonucleotide. The oligonucleotide is designed based on a target sequence present in an RNA molecule, and the cleavage of the RNA molecule is inter alia carried out at conditions allowing the hybridization of the oligonucleotide to the target 5 sequence. Thereby, the method is easily applicable to RNA molecules of any sequence. The method further involves the analysis of the RNA fragments obtained after cleavage to obtain information on the physical properties of the RNA molecule.
    Type: Application
    Filed: December 20, 2019
    Publication date: March 10, 2022
    Applicant: CureVac AG
    Inventors: Alexander SCHWENGER, Stefan HEINZ, Tilmann ROOS, Benyamin YAZDAN PANAH, Veronika WAGNER
  • Patent number: 11248223
    Abstract: The present invention relates to a buffer system comprising a dicarboxylic acid or tricarboxylic acid or a salt thereof for synthesizing RNA molecules as well as a method of RNA in vitro transcription using this buffer system. The present invention also provides the use of this buffer system in RNA in vitro transcription and in the reduction or prevention of precipitates during RNA in vitro transcription.
    Type: Grant
    Filed: December 23, 2016
    Date of Patent: February 15, 2022
    Assignee: CureVac AG
    Inventors: Benyamin Yazdan Panah, Aniela Wochner, Tilmann Roos, Andreas Funkner, Martin Kunze
  • Patent number: 11179337
    Abstract: The present invention is directed to a storage-stable formulation of long-chain RNA. In particular, the invention concerns a dry powder composition comprising a long-chain RNA molecule. The present invention is furthermore directed to methods for preparing a dry powder composition comprising a long-chain RNA molecule by spray-drying. The invention further concerns the use of such a dry powder composition comprising a long-chain RNA molecule in the preparation of pharmaceutical compositions and vaccines, to a method of treating or preventing a disorder or a disease, to first and second medical uses of such a dry powder composition comprising a long-chain RNA molecule and to kits, particularly to kits of parts, comprising such a dry powder composition comprising a long-chain RNA molecule.
    Type: Grant
    Filed: November 11, 2019
    Date of Patent: November 23, 2021
    Assignee: CureVac AG
    Inventors: Fabian Johannes Eber, Benyamin Yazdan Panah, Stefanie Sewing, Thomas Ketterer, Thorsten Mutzke, Tilmann Roos, Michael Sonntag, Michael Wiggenhorn, Katharina Kolland
  • Publication number: 20210261897
    Abstract: The present invention relates to a bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing. Further, the use of a bioreactor for RNA in vitro transcription as described herein is part of the present invention. The present invention relates to an RNA in vitro transcription reactor designed to be operable in an automated manner under GMP-compliant conditions. In particular, said RNA in vitro transcription reactor allows repetitive use of DNA template for various RNA in vitro transcription reactions. Further, the invention relates to an apparatus for RNA manufacturing comprising (a) a module for template DNA synthesis, (b) a module for transcribing DNA into RNA comprising said RNA in vitro transcription reactor, and, optionally, (c) a module for RNA formulation.
    Type: Application
    Filed: June 28, 2019
    Publication date: August 26, 2021
    Applicants: CureVac AG, Tesla Grohmann Automation GmbH
    Inventors: Benyamin YAZDAN PANAH, Tilmann ROOS, Martin KUNZE, Felix BERTSCH, Aniela WOCHNER, Michael RAUEN, Philipp HOFFMANN